Complex | |
AACDB_ID: | 6889 |
PDBID: | 4JLR |
Chains: | AB_C |
Organism: | Homo sapiens |
Method: | XRD |
Resolution (Å): | 2.71 |
Reference: | 10.1038/nature12966 |
Antibody | |
Antibody: | Motavizumab Fab |
Antibody mutation: | No |
INN (Clinical Trial): | |
Antigen | |
Antigen: | Designed respiratory syncytial virus immunogen |
Antigen mutation: | No |
Durg Target: |
Antibody
Heavy Chain: A
Mutation: NULL
>4JLR_A|Chain A, D[auth H]|Motavizumab Fab heavy chain|Homo sapiens (9606) QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSANQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK |
Light Chain: B
Mutation: NULL
>4JLR_B|Chain B, E[auth L]|Motavizumab Fab light chain|Homo sapiens (9606) DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTAFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Antigen
Chain: C
Mutation: NULL
>4JLR_C|Chain C, F[auth S]|RSV_1Isea designed scaffold| GSRSDMRKDAERRFDKFVEAAKNKFDKFKAALRKGDIKEERRKDMKKLARKEAEQARRAVRNRLSELLSKINDMPITNDQKKLMSNDVLKFAAEAEKKIEALAADAEDKFTQGSWLEHHHHHH |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
A: ALA32 GLY33 TRP52 TRP53 ASP54 LYS56 ILE97 PHE98 ASN99 B: GLY31 TYR32 ASP50 GLY91 SER92 TYR94 C: SER65 LEU68 SER69 ILE71 ASN72 ASP73 THR77 ASN78 ASP79 LYS81 LYS82 LEU83 SER85 ASN86 LEU89 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)